Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Helius Secures Major Grant For $2.4m R&D Project

Helius Therapeutics has confirmed it’s the recipient of a substantial grant for its New Zealand-based cultivation, plant breeding and medicines research programme.

The $2.4 million research and development project has been approved for co-funding of up to 28% by New Zealand’s innovation agency, Callaghan Innovation. Supporting innovative and high-performing R&D businesses, the agency has committed to contributing up to nearly $600,000 (excluding GST) to Kiwi-owned Helius Therapeutics over the next three years.

Chief Science Officer at Helius, Dr Jim Polston, says Callaghan Innovation’s co-funding will help Helius advance unique cannabis genetics and develop safe, consistent, and high-quality, novel cannabis medications for clinical trials.

As New Zealand’s largest medicinal cannabis biotechnology company, Helius is currently completing its $20m state-of-the-art GMP (Good Manufacturing Practice) facility in East Auckland. It is focused on cannabis cultivation, cannabis oil extraction, advanced cannabinoid research, and medicines manufacturing.

“Healthcare professionals want medicinal cannabis to meet traditional pharmaceutical standards and, to gain regulatory approval, our products will go through extensive clinical trials. Our focus at Helius is to unlock the vast potential of cannabis to develop novel medicines, targeting specific health conditions, which are ideal candidates for clinical trials. Ultimately, that’s what this co-funding will help us deliver,” he says.

He says with an initial focus on treating pain, sleep and neurological disorders, Helius’ breeding programme will allow for the development of a library of unique genetic material, focusing on cultivars with strong potential to treat specific conditions.

As well as creating the highest quality medicinal cannabis for product development, Helius’ R&D work also aims to optimise indoor cultivation conditions. This includes Helius’ New Zealand-exclusive partnership with BioLumic to implement proprietary UV treatments, and creating unique, reproducible cultivation methods.

Dr Polston says compared to other plant-based medicines, cannabis presents unique technical challenges, given there are about 400 different chemical entities in the plant and a universal lack of understanding around which constituents produce certain beneficial effects.

He says creating consistency around the plant and its extracts, and isolating certain constituents, is challenging but paramount to creating standardised cannabis medicines.

“Over the last five decades, cannabis has been selectively bred for high THC content. Too little attention has been placed on breeding the minor phytocannabinoids, of which there are several non-intoxicating varieties with exciting medicinal potential. Isolation and purification of minor cannabinoids has proven difficult but remains incredibly desirable.”

Dr Polston says the creation of a substantial and robust local genetic breeding programme by Helius will help put New Zealand in a unique position to lead the global market in R&D, with the country ideally suited for cost-efficient clinical trials.

Chief Executive of Helius Therapeutics, Paul Manning, says Helius’ medicinal cannabis products will be world leading in their efficaciousness, safely substituting or sparing many conventional pharmaceutical products. Helius is also innovating and developing optimal indoor cultivation methods, completely new to the cannabis industry globally.

“This significant co-funding awarded by Callaghan Innovation will not only help us deliver quality, affordable cannabis medicines to thousands of Kiwi patients, but our R&D, which is happening right here in New Zealand, will be transferrable to many export markets. When we think about reigniting the country’s economy after Covid-19, what better opportunity than highly innovative, ‘New Zealand Made’ medicines development,” says Mr Manning.

Dr Jim Polston says Helius is strongly placed to be a global leader in cannabis technologies, working collaboratively with a range of specialist scientific partners, while complementing and extending international research.

“We are honoured to receive this level of support, and look forward to bringing next-generation cannabis therapies to patients across New Zealand and the world,” he says.

© Scoop Media

Business Headlines | Sci-Tech Headlines


DIY Law: Government Exempts Some Home Improvements From Costly Consents

Homeowners, builders and DIYers will soon have an easier time making basic home improvements as the Government scraps the need for consents for low-risk building work such as sleep-outs, sheds and carports – allowing the construction sector ... More>>


Media Awards: The New Zealand Herald Named Newspaper Of The Year, Website Of The Year At Voyager Media Awards

The New Zealand Herald has been labelled a “powerhouse news operation” as it claims the two biggest prizes – Newspaper of the Year and Website of the Year – along with many individual awards at the 2020 Voyager Media Awards Website of the ... More>>


ASB Bank: ASB Takes The Lead Again With New Low Home Loan Interest Rate

ASB has moved again to support its customers, cutting a number of home loan rates, including the two-year special rate to a new low of 2.69% p.a. Craig Sims, ASB executive general manager Retail Banking says the reduced rate will be welcome news for many ... More>>


Nathan Hoturoa Gray: The Problems With Testing And Case Statistics For Covid-19

To begin to understand disease transmission in a country requires adequate testing of your population with properly vetted, accurate tests. As the world struggles to find what 'adequate percentage' of the population is necessary, (estimates predict ... More>>


RNZ: Fletcher Building To Lay Off 1000 Staff In New Zealand

The construction company will cut around 10 percent of its workforce as it struggles with the fallout from Covid-19. More>>


Can Pay, Won't Pay: Cashflow Moves Urged

Government Ministers are asking significant private enterprises to adopt prompt payment practices in line with the state sector, as a way to improve cashflow for small businesses. More>>


Gordon Campbell: On Why We Should Legally Protect The Right To Work From Home

For understandable reasons, the media messaging around Level Two has been all about “freedom” and “celebration”, but this is not necessarily going to be a universal experience. When it comes to workplace relations, Level Two is just as likely to ... More>>


Telecoms: Spark Welcomes Spectrum Allocation And Prepares For 5G Rollout Over The Next 12 Months

Spark welcomes spectrum allocation and prepares for 5G rollout over the next 12 months Spark today welcomed the announcement of the direct allocation process of 5G spectrum, with the Company to be offered management rights to 60 MHz of 3.5 GHz ... More>>


Trade: Record Monthly Surplus As Imports Dive

Imports in April 2020 had their biggest fall since October 2009, resulting in a monthly trade surplus of $1.3 billion, Stats NZ said today. “This is the largest monthly trade surplus on record and the annual goods trade deficit is the lowest ... More>>


Media Blues: Stuff Chief Executive Buys Company For $1

Stuff chief executive Sinead Boucher has purchased Stuff from its Australian owners Nine Entertainment for $1.
The chief executive was returning the company to New Zealand ownership, with the sale is expected to be completed by 31 May.
"Our plan is to transition the ownership of Stuff to give staff a direct stake in the business as shareholders," Boucher said in a statement.... More>>


RNZ: Bar Reopening Night 'much, Much Quieter'

Pubs and bars are reporting a sluggish first day back after the lockdown, with the fear of going out, or perhaps the joy of staying home, thought to be a reason for the low numbers. More>>


Stats NZ: New Zealand’s Population Passes 5 Million

New Zealand's resident population provisionally reached 5 million in March 2020, Stats NZ said today. More>>

NIWA: Seven Weeks Of Clearing The Air Provides Huge Benefits: Scientist

Seven weeks of lockdown has provided evidence of how pollution can vanish overnight with benefits for the environment and individuals, says NIWA air quality scientist Dr Ian Longley. Dr Longley has been monitoring air quality in Auckland, Wellington ... More>>


Government: Tax Changes Throw Cash Lifeline To SMEs

A significant package of tax reforms will be pushed through all stages in Parliament today to throw a cash flow lifeline to small businesses. More>>


Statistics: Some Indicators Pick Up As New Zealand Moves Out Of Lockdown

New Zealanders moved around more in the main centres and used more fuel and power while weekly exports held up as the country left the COVID-19 level 4 lockdown, Stats NZ said today. COVID-19 data porta l, our new webpage, includes about 40 near-real-time ... More>>


University Of Canterbury: Astronomers Discover The Science Behind Star Bursts That Light Up The Sky

University of Canterbury (UC) astronomers are part of an international team that has revealed how explosions on the surface of a white dwarf star can increase its brightness by thousands or millions of times making it look like a new star. For ... More>>

RNZ: International Passenger Numbers At Auckland Airport Drop 95 Percent

Auckland Airport says international passengers numbers have dropped more than 95 percent in the first 20 days of April over the year earlier. More>>